Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 41

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 41
---
 or will exceed, $120,000 (or,                               
 if less, 1% of the average of our total asset amounts at December 31, 2023 and 2024); and |

| ● | any director, executive officer, holder of 5% or more of                                                                                 
 any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, 
 or will have, a direct or indirect material interest.                                                                                    |

CERo Relationships and Related Party Transactions Collaboration and Option Agreement On March 3, 2020, Legacy CERo entered into a collaboration and option agreement (“Collaboration Agreement”) with a collaborative partner that was an investor of Legacy CERo, pursuant to which each party was granted a royalty-free, nonexclusive, worldwide license to share the other party’s technologies to create bi-functional T-cells. Legacy CERo was responsible for all employee and other internal costs incurred in the performance of all of Legacy CERo’s R&D activities, with approved cost overruns funded by the collaborative partner. At the end of the research project, the collaborative partner would be granted the option to enter into an exclusive license for the further development of the combined drug. Under the Collaboration Agreement, the collaborative partner paid us $0 for the year ended December 31, 2023. The Collaboration Agreement terminated on March 3, 2023. PIPE Financings In February 2024, we issued and sold an aggregate of 10,039 shares of Series A Preferred Stock, 6,127 Series A Warrants and 2,500 Preferred Warrants, at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to $2.0 million if the Preferred Warrants are exercised. 21 The following table summarizes the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers(1)                          |     | Shares of 
 Series A  
 Preferred 
 Stock     |       |     | Total    
 Purchase 
 Price    |           |
|:---------------------------------------|:----|:----------|------:|:----|:---------|----------:|
| Daniel Corey(2)                        |     |           |   150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000(3) |     |